BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
1002 results:

  • 1. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Deep phenotyping of dementia in a multi-ethnic cardiovascular cohort: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Ostovaneh MR; Hughes TM; Wu CO; McClelland RL; Casanova R; Bluemke DA; Tracy RP; Shea S; Heckbert SR; Lima JAC; Ambale-Venkatesh B
    PLoS One; 2024; 19(4):e0298952. PubMed ID: 38635767
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
    Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
    Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. il-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept.
    Roser LA; Sakellariou C; Lindstedt M; Neuhaus V; Dehmel S; Sommer C; Raasch M; Flandre T; Roesener S; Hewitt P; Parnham MJ; Sewald K; Schiffmann S
    J Immunotoxicol; 2024 Dec; 21(1):2332177. PubMed ID: 38578203
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
    Na K; Lee S; Kim DK; Kim YS; Hwang JY; Kang SS; Baek S; Lee CY; Yang SM; Han YJ; Kim MH; Han H; Kim Y; Kim JH; Jeon S; Byeon Y; Lee JB; Lim SM; Hong MH; Pyo KH; Cho BC
    Front Immunol; 2024; 15():1336246. PubMed ID: 38515751
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Antiproliferative and immunomodulative potential of Citrullus colocynthis and its bioactive compounds in human lymphocytes and lung cells.
    Stein C; Voigts J; Niederreiter L; Kowarschik S; Huber R; Lüth VM
    J Ethnopharmacol; 2024 Jun; 328():118053. PubMed ID: 38499257
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Mathematical modeling and control of lung cancer with il2 cytokine and anti-PD-L1 inhibitor effects for low immune individuals.
    Ahmad A; Kulachi MO; Farman M; Junjua MU; Bilal Riaz M; Riaz S
    PLoS One; 2024; 19(3):e0299560. PubMed ID: 38483931
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
    Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
    J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Interleukin-2-induced skin inflammation.
    Sommer C; Cohen JN; Dehmel S; Neuhaus V; Schaudien D; Braun A; Sewald K; Rosenblum MD
    Eur J Immunol; 2024 Apr; 54(4):e2350580. PubMed ID: 38430129
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations.
    Cappelletto E; Fasiolo LT; Salizzato V; Piccin L; Fabozzi A; Contato A; Bianco PD; Pasello G; Chiarion-Sileni V; Gion M; Fabricio ASC
    Int J Biol Markers; 2024 Mar; 39(1):9-22. PubMed ID: 38407953
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
    Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
    Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.
    Borgers JSW; van Schijndel AW; van Thienen JV; Klobuch S; Seijkens TTP; Tobin RP; van Heerebeek L; Driessen-Waaijer A; Rohaan MW; Haanen JBAG
    ESMO Open; 2024 Feb; 9(2):102383. PubMed ID: 38364453
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Cytotoxic Programming of CD4+ T Cells Is Regulated by Opposing Actions of the Related Transcription Factors Eos and Aiolos.
    Jones DM; Tuazon JA; Read KA; Leonard MR; Pokhrel S; Sreekumar BK; Warren RT; Yount JS; Collins PL; Oestreich KJ
    J Immunol; 2024 Apr; 212(7):1129-1141. PubMed ID: 38363226
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer.
    Sundström P; Dutta N; Rodin W; Hallqvist A; Raghavan S; Quiding Järbrink M
    Oncoimmunology; 2024; 13(1):2312631. PubMed ID: 38343750
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
    Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Efficacy against lung cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
    Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
    J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma.
    Yu T; Nie FQ; Zhang Q; Yu SK; Zhang ML; Wang Q; Wang EX; Lu KH; Sun M
    Cell Death Dis; 2024 Jan; 15(1):12. PubMed ID: 38182561
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Pan-cancer analysis of homeodomain-containing gene C10 and its carcinogenesis in lung adenocarcinoma.
    Tan X; Li Z; Xie H; Chen J; Xiao J; Zhi Y; Mo H; Huang Y; Liu A
    Aging (Albany NY); 2023 Dec; 15(24):15243-15266. PubMed ID: 38154103
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
    Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
    Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association of white matter hyperintensities with long-term EGFR-TKI treatment and prediction of progression risk.
    Yang H; Meng R; Jiang J; Luo Y; Deng X; Yang S; Chen S; Wu J; Wan Y; Li Y; Jin H; He Q; Wang D; Chang J; Yang K; Zhou Y; Hu B
    Brain Behav; 2023 Dec; 13(12):e3326. PubMed ID: 38054663
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 51.